CTMX
CytomX Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$916.59M
P/E Ratio
—
EPS
$-0.15
Beta
2.48
52W High
$8.21
52W Low
$0.53
50-Day MA
$5.18
200-Day MA
$3.64
Dividend Yield
—
Profit Margin
-22.80%
Forward P/E
14.20
PEG Ratio
-1.80
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $76.20M |
| Gross Profit (TTM) | $76.20M |
| EBITDA | $-18.19M |
| Operating Margin | -3791.00% |
| Return on Equity | -35.20% |
| Return on Assets | -8.99% |
| Revenue/Share (TTM) | $0.55 |
| Book Value | $0.58 |
| Price-to-Book | 9.92 |
| Price-to-Sales (TTM) | 12.03 |
| EV/Revenue | 11.15 |
| EV/EBITDA | 24.67 |
| Quarterly Earnings Growth (YoY) | 60.60% |
| Quarterly Revenue Growth (YoY) | -98.30% |
| Shares Outstanding | $216.18M |
| Float | $147.96M |
| % Insiders | 0.66% |
| % Institutions | 72.89% |
Historical Volatility
HV 10-Day
53.40%
HV 20-Day
182.48%
HV 30-Day
156.22%
HV 60-Day
129.41%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($13.67 target)
2
Strong Buy5
Buy2
HoldData last updated: 4/10/2026